TICKERNERD
Menu
ALMRHealthcare · Medical Devices

ALMR Stock Forecast: Alamar Biosciences, Inc. (California) Price Predictions for 2026-2027

Last close, 14 Oct 2026
$25
+7.87% on the day

The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) hold a median 12-month price target of $34 — +34.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.6B
Ticker Nerd rank
4 / 100
Median analyst target
$34
Analysts covering
5
Revenue$29.4M
Operating income−$13.5M
Net income−$13.2M
Free cash flow−$15.1M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.6%
1M
−9.4%
From high
−33.5%
From low
+32.9%
$19
$38
Range since 17 Apr 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

ALMR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alamar Biosciences, Inc. (California) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
85
Size
37
Value
12
Accruals
8
Growth
8
Momentum
8
Issuance
4
Volatility
3
Quality
3

Revisions (85): Analysts have, on balance, been raising their forecasts.

Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Apr 2026Adjusted close, US dollars
$15$20$25$30$35$40$45$50May 26Jun 26Jul 26Aug 26Sep 26Oct 26ALMRHigh $45Median $34Low $31

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $31Median $34High $45

The green dot is the last close — the median target sits +34.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026JP MorganMaintainsOverweight$32 → $35
11 Aug 2026StifelMaintainsBuy$28 → $32
12 May 2026JP MorganInitiatesOverweight—
12 May 2026JP MorganInitiatesOverweight$30
12 May 2026Leerink PartnersInitiatesOutperform—
12 May 2026Leerink PartnersInitiatesOutperform$35
12 May 2026StifelInitiatesBuy—
12 May 2026StifelInitiatesBuy$28
12 May 2026TD CowenInitiatesBuy—
12 May 2026TD CowenInitiatesBuy$30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALMR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALMR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

ALMR vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160May 26Jun 26Jul 26Aug 26Sep 26Oct 26ALMRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Alamar Biosciences, Inc. (California) (ALMR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−52.4×

Cheaper than 99% of US stocks

Price / sales
16.3×

Cheaper than 10% of US stocks

Price / book
5.2×

Cheaper than 18% of US stocks

EV / EBITDA
−38.2×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
82.1%

Higher than 91% of US stocks

Earnings growth (YoY)
—
Gross margin
60.2%

Higher than 73% of US stocks

Operating margin
−46.0%

Higher than 17% of US stocks

Net margin
−49.5%

Higher than 10% of US stocks

Returns & dividend
Return on equity
18.8%

Higher than 80% of US stocks

Return on assets
−21.3%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alamar Biosciences, Inc. (California) (ALMR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alamar Biosciences, Inc. (California) has a market value of $1.6B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $84.7M. The latest quarter grew 82.1% year on year.

  • Net income over the same four quarters: −$49.2M, a −58.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.76.

  • Free cash flow in the twelve months to 30 June 2026: −$63.2M, after $1.1M of capital spending.

  • Shares outstanding: 69.4M.

  • Trailing P/E: −52.4×; forward P/E: −43.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alamar Biosciences, Inc. (California) employs 286 people — $296K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

ALMR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ALMRAlamar Biosciences, Inc. (California)$1.6B
4
ESTAEstablishment Labs Holdings, Inc.$1.7B
74
NVCRNovoCure Ltd.$1.6B
96
ATECAlphatec Holdings, Inc.$1.6B
74
INSPInspire Medical Systems, Inc.$1.9B
87
AXGNAxogen, Inc.$2.1B
80
BFLYButterfly Network, Inc.$2.1B
75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alamar Biosciences, Inc. (California) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALMR news & analysis

Alamar: The Consumables Flywheel Is Just Getting Started

Seeking Alpha · 8 Oct 2026positive

Seeking Alpha reported that Alamar Biosciences’ 2Q26 revenue rose 82% year over year to $29.4 million, while consumables revenue increased 147% and exceeded half of total revenue. Gross margin improved to 60% amid manufacturing efficiencies and a higher consumables mix, although elevated operating expenses continued to drive losses.

Why it matters — The results highlight growth in recurring consumables and improved margins, alongside ongoing losses from substantial investment.

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team

GlobeNewsWire · 5 Oct 2026positive

Alamar Biosciences announced it has named former Grail CEO Bob Ragusa to its board of directors and expanded its leadership team with the appointments of John Brottem as general counsel and Amelia Merrill as chief people officer.

Why it matters — Adding an experienced industry leader to the board and strengthening executive roles signals a boost to Alamar's corporate leadership and governance as it continues to grow.

Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment

GlobeNewsWire · 24 Sept 2026neutral

A study published in Lancet Neurology used Alamar Biosciences' technology and found that blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab, an Alzheimer's treatment.

Why it matters — The study highlights the application of Alamar's technology in Alzheimer's research, potentially demonstrating the utility of its platform in distinguishing biological responses in a major therapeutic area.

Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Alamar Biosciences, Inc. (ALMR) presented at the Morgan Stanley 24th Annual Global Healthcare Conference. A transcript of the presentation has been published on Seeking Alpha.

Why it matters — A conference presentation transcript gives ALMR watchers direct insight into management's messaging and strategic positioning shared with investors and analysts.

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Alamar Biosciences, Inc. (Nasdaq: ALMR) announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference to be held in New York, NY. The company, a leader in precision proteomics, made the announcement on September 1, 2026.

Why it matters — The company's participation in a major industry conference provides an opportunity for Alamar to present its precision proteomics platform to a broad audience of investors and healthcare professionals.

FAQ

Frequently asked questions about ALMR stock

What is the ALMR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) have a median 12-month price target of $34, with estimates ranging from $31 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALMR stock a buy right now?

Of the 5 analysts covering Alamar Biosciences, Inc. (California), 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alamar Biosciences, Inc. (California) 4 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALMR?

As at 14 Oct 2026, Alamar Biosciences, Inc. (California) ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (85 of 100).

Will ALMR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +34.0% from the last close, and Ticker Nerd's factor model ranks Alamar Biosciences, Inc. (California) 4 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALMR stock forecast for 2030?

No analyst covering Alamar Biosciences, Inc. (California) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $45 over the next 12 months.

What does Alamar Biosciences, Inc. (California) do?

Alamar Biosciences Inc. is a proteomics company focused on developing tools for protein biomarker detection and analysis.

What is the latest news on ALMR?

The most recent item we track (Seeking Alpha, 8 Oct 2026): "Alamar: The Consumables Flywheel Is Just Getting Started". Seeking Alpha reported that Alamar Biosciences’ 2Q26 revenue rose 82% year over year to $29.4 million, while consumables revenue increased 147% and exceeded half of total revenue. Gross margin improved to 60% amid manufacturing efficiencies and a higher consumables mix, although elevated operating expenses continued to drive losses.

Company

About Alamar Biosciences, Inc. (California).

Alamar Biosciences Inc. is a proteomics company focused on developing tools for protein biomarker detection and analysis. Its core platform, NULISA technology, supports ultra-sensitive liquid biopsy workflows designed to measure disease-related proteins from small biofluid samples. The company offers instruments, consumables, assays, and related services built around its precision proteomics platform, including the ARGO high-throughput system and NULISAseq and NULISAqpcr assay products. Alamar Biosciences serves research and translational science customers across immunology, neurology, oncology, and other areas of disease research. Its products are used by academic institutions, biopharmaceutical companies, contract research organizations, and service laboratories that need high-plex protein analysis for biomarker discovery and diagnostic development. Based in Fremont, California, Alamar Biosciences plays a specialized role in the life sciences tools market by enabling advanced protein detection for early disease research and clinical innovation.

CEO Dr. Yuling Luo Ph.D. · 286 employees · United States · https://alamarbio.com